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AbstrACt
Introduction BRCA1 mutation carriers have a significant 
lifetime risk of breast cancer, with their primary risk-
reduction option being bilateral mastectomy. Preclinical 
work from our laboratory demonstrated that in BRCA1-
deficient breast cells, oestrogen and its metabolites are 
capable of driving DNA damage and subsequent genomic 
instability, which are well-defined early events in BRCA1-
related cancers. Based on this, we hypothesise that a 
chemopreventive approach which reduces circulating 
oestrogen levels may reduce DNA damage and genomic 
instability, thereby providing an alternative to risk-reducing 
surgery.
Methods and analysis 12 premenopausal women 
with pathogenic BRCA1 mutations and no previous 
risk-reducing surgery will be recruited from family 
history clinics. Participants will be allocated 1:1 to two 
arms. All will undergo baseline breast biopsies, blood 
and urine sampling, and quality of life questionnaires. 
Group A will receive goserelin 3.6 mg/28 days by 
subcutaneous injection, plus oral anastrozole 1 mg/day, 
for 12 weeks. Group B will receive oral tamoxifen 20 mg/
day for 12 weeks. Following treatment, both groups will 
provide repeat biopsies, blood and urine samples, and 
questionnaires. Following a 1-month washout period, the 
groups will cross over, group A receiving tamoxifen and 
group B goserelin and anastrozole for a further 12 weeks. 
After treatment, biopsies, blood and urine samples, and 
questionnaires will be repeated. DNA damage will be 
assessed in core biopsies, while blood and urine samples 
will be used to measure oestrogen metabolite and DNA 
adduct levels.
Ethics and dissemination This study has ethical 
approval from the Office for Research Ethics Committees 
Northern Ireland (16/NI/0055) and the Medicines and 
Healthcare products Regulatory Agency (MHRA) (reference: 
32485/0032/001–0001). The investigational medicinal 
products used in this trial are licensed and in common use, 
with well-documented safety information. Dissemination 
of results will be via high-impact journals and relevant 
national/international conferences. A copy of the results 
will be offered to the participants and be made available to 
patient support groups.
trial registration number EudraCT: 2016-001087-11; 
Pre-results.
IntroduCtIon 
Women with a germline BRCA1 mutation 
have up to an 85% lifetime risk of devel-
oping breast cancer by age 70, with the 
majority of these women developing triple 
negative disease.1 2 Intriguingly, a number 
of retrospective studies, including a large 
meta-analysis, have demonstrated that 
risk-reducing oophorectomy significantly 
reduces the risk of developing breast 
cancer in this population by up to 50%.3 4 
strengths and limitations of this study
 ► Solid underpinning preclinical data generated within 
our laboratory.
 ► Extensive patient and public involvement in study 
design and development.
 ► Oestrogen and oestrogen metabolite levels assessed 
using established, highly sensitive mass spectrome-
try-based methodology.
 ► Lack of qualitative intervention to support recruit-
ment and investigate reasons for declining study 
participation.
 ► DNA damage is not currently a validated biomarker 
for cancer risk. 
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In contrast, more recent studies, including a prospec-
tive study, contradict this, suggesting some protective 
effect in BRCA2 but not BRCA1 mutation carriers.5 6 
However, these studies have limited follow-up (mean 
follow-up period of 5.6 and 3.2 years respectively), 
and it is clear from chemoprevention studies carried 
out in large populations of women at increased risk 
that a limited chemopreventive effect is seen before 
5 years, with significantly greater protective effects 
seen beyond 10 years.7 Furthermore, oophorectomy 
in a mammary-specific BRCA1 knockout mouse model 
reduces mammary tumour formation as compared with 
non-oophorectomised mice.8 Taking this together, the 
evidence suggests that oophorectomy may confer a 
protective effect in BRCA1 mutation carriers; however, 
long-term prospective data are required to support 
this. Currently, risk-reducing mastectomy is the main-
stay of preventative treatment offered to BRCA1 muta-
tion carriers, which is effective but carries significant 
associated costs in terms of physical and psychological 
morbidity and healthcare spending.9–11 Aside from 
risk-reducing mastectomy, the only other risk-reduction 
strategy available to these women is chemoprevention.
In the UK, the National Institute for Health and Care 
Excellence recommends the selective oestrogen receptor 
modulators (SERMs) tamoxifen and raloxifene for use in 
women at high risk of developing breast cancer, on the 
basis that they have been demonstrated to reduce the inci-
dence of oestrogen-receptor positive tumours.12 However, 
evidence on the benefit of tamoxifen as a chemopreven-
tive agent in BRCA1 mutation carriers is conflicting. One 
small study showed no benefit from tamoxifen in reducing 
breast cancer risk in BRCA1 mutation carriers, although 
it has been suggested that tamoxifen use in BRCA1 muta-
tion carriers with breast cancer may reduce the incidence 
of contralateral tumours.13 14 In one case–control study, 
short-term (2-year) tamoxifen use was as protective for 
contralateral breast cancer as a longer (5-year) course in 
BRCA1 and BRCA2 mutation carriers, suggesting some 
potential chemopreventive efficacy.15 
However, given that the majority of tumours that develop 
in BRCA1 mutation carriers are oestrogen receptor 
(ER)-negative, it seems counterintuitive that SERMs will 
reduce breast cancer risk, given that no benefit in ER-neg-
ative tumours has been shown in the chemoprevention 
setting with tamoxifen.12
Clinical trial data from the  Second International Breast 
Cancer Intervention Study (IBIS-II) suggest a reduction 
in breast cancer risk using aromatase inhibitors (AI) in 
women with increased risk.16 However, there is no direct 
evidence to support a benefit for this approach in BRCA1 
mutation carriers.
Clearly oestrogen plays a key role in tumourigenesis in 
these patients, as tumours develop preferentially in the 
oestrogen-rich tissues of the breast and ovary.
Preclinical data from our laboratory demonstrate 
that oestrogen and oestrogen metabolites cause DNA 
double strand breaks (DSBs) in ER-negative breast 
cells (normal and cancer cell lines, as well as primary 
breast progenitor cells isolated from patients), and 
that BRCA1 is necessary for repression and repair of 
these DSBs.17 The implication of these findings is that 
in BRCA1-deficient breast cells, exposure to oestrogen 
and its metabolites is capable of driving genomic insta-
bility, a well-defined early event in BRCA1-related 
cancer development.18 19
Taken with evidence from clinical trials, which demon-
strate no benefit from SERMs in reducing the incidence 
of ER-negative tumours, this suggests that SERMs are 
unlikely to be effective chemopreventive agents in BRCA1 
mutation carriers (who are more likely to develop ER-neg-
ative tumours). Our data suggest that a chemopreven-
tive approach which lowers circulating oestrogen levels 
and reduces exposure to oestrogen metabolites within 
the breast tissue may be more successful by removing this 
driver of genomic instability. While DNA damage is not 
at present a validated biomarker of cancer risk in muta-
tion carriers, as described earlier, genomic instability is 
a well-characterised early hallmark of BRCA1-associated 
breast tumours. Consistent with this, mice harbouring 
specific point mutations within BRCA1 affecting its DNA 
repair function while conserving other protein functions 
(E3 ligase, transcriptional activity and so on) develop 
tumours.20 This supports the link between DNA damage, 
genomic instability and tumourigenesis in BRCA1-defi-
cient breast cells.
In postmenopausal women (or premenopausal women 
who have undergone oophorectomy), the use of an AI 
may be considered. In premenopausal women with intact 
ovaries, the induction of reversible ovarian suppression 
using a luteinising hormone releasing hormone agonist 
(LHRHa) in combination with an AI, to suppress subse-
quent aromatase-mediated oestrogen production, may be 
effective.
Progesterone signalling has also recently been impli-
cated in BRCA1-related tumourigenesis, with the tumour 
necrosis factor superfamily member RANK (receptor acti-
vator of nuclear factor κ B) and its corresponding ligand 
RANKL (ligand of receptor activator of nuclear factor κ 
B) functioning as key factors in this pathway and poten-
tial targets for chemoprevention.21 Importantly, LHRHa 
suppression of the hypothalamic-pituitary axis will also 
result in decreased progesterone levels, which will conse-
quently reduce progesterone-dependent RANK/RANKL 
signalling. Additionally, expression of the progesterone 
receptor (PR), a critical mediator of the progesterone/
RANK/RANKL pathway, is itself driven by oestrogen 
signalling through the ER. Taken together, the suppres-
sion of oestrogen is likely to provide chemopreventive 
potential, similar to or surpassing that demonstrated 
through RANK/RANKL suppression.
Although LHRHa, AIs and SERMs are used in breast 
cancer and fertility treatments, there are no published 
data in the context of BRCA1-specific chemoprevention 
where the intention is to prevent ER-negative breast 
cancer.
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It is known that compliance and acceptability of these 
agents in the adjuvant setting of breast cancer treatment 
are good, although with a high frequency of side effects.22
The compliance of women taking SERMs for chemo-
prevention is suboptimal, with approximately 40% of 
women unable to complete 5 years of therapy because 
of side effects.23 Therefore, compliance with LHRHa in 
combination with an AI in the chemopreventive setting 
must be assessed and compared with SERM data as an 
important consideration in the feasibility of use in this 
context. In line with this, this study aims to inform future 
tolerability and compliance evaluation in a cohort who 
may require long durations of treatment and have a long 
life expectancy.
If the results from this study demonstrate that these 
treatments are a feasible and tolerable strategy, and 
that DNA damage is reduced through reduced levels of 
circulating oestrogen, this would provide data to support 
the proposed mechanism of oestrogen-driven tumouri-
genesis in BRCA1 mutation carriers. Furthermore, this 
may provide evidence to support further studies evalu-
ating the use of this chemopreventive strategy in BRCA1 
mutation carriers. Nevertheless, this would require a 
multicentre international collaborative study, which pres-
ents significant challenges. Undoubtedly the treatment 
regimen proposed within this study has a clear side-effect 
profile, the tolerability and acceptability of which will be 
addressed in this study. Currently, a number of groups are 
investigating inhibition of progesterone and/or RANK/
RANKL signalling as an alternative chemopreventive 
strategy in BRCA1 carriers, which may present a more 
tolerable approach.24 However, a recent study using a 
well-characterised mouse model of BRCA1-associated 
breast cancer suggests that oestrogen is the predominant 
driver of tumourigenesis rather than progesterone.25 
Given that RANK/RANKL signalling is progesterone-de-
pendent, the efficacy of these progesterone and RANK/
RANKL-targeted chemopreventive approaches remains 
unproven. In light of this, continued exploration of 
oestrogen suppression in this cohort is justified in order 
to maximise the repertoire of potential chemopreventive 
options in this area of unmet clinical need.
MEthods/AnAlysIs
Aims, design and setting of the study
The principal aim of this research is to establish if these 
treatments are tolerable and to evaluate patient compli-
ance. The secondary aims include tolerability of treat-
ments and quality of life (QOL).
As exploratory objectives, this research seeks to 
confirm the link between oestrogen exposure and DSBs 
and generate further insight into how oestrogen and its 
metabolites affect tumourigenic transformation, and to 
generate preliminary data necessary to support the devel-
opment of a larger clinical study to evaluate chemopre-
vention in BRCA1 mutation carriers.
The study aims and objectives are summarised in 
table 1.
Table 1 Trial objectives and endpoints
Primary objective Primary endpoint
To establish the acceptability of trial treatments as a 
chemopreventive strategy in BRCA1 mutation carriers and 
compliance.
Percentage of patients given patient information sheet who 
consent to trial entry.
Measurement of compliance with treatment using patient 
medication cards.
Secondary objective Secondary endpoint
To establish tolerability of trial treatments and procedures. Measurement of patient quality of life using questionnaires at 
baseline and after completion of each treatment arm.
Recording of adverse events that occur during treatment.
Exploratory objectives Exploratory endpoints
To establish the potential of chemopreventive agents to reduce 
oestrogen-mediated DNA damage in breast tissue in BRCA1 
mutation carriers.
Measurement of DNA damage in breast tissue using comet 
assays and immunohistochemical assays at baseline and after 
completion of each treatment arm.
To establish the effect of treatment on oestrogen metabolite 
levels in breast tissue, urine and serum.
Measurement of breast, blood and urinary oestrogen 
metabolite levels using ultra performance liquid 
chromatography tandem mass spectrometry at baseline and 
after completion of each treatment arm.
To explore the mechanism of oestrogen-mediated DNA 
damage in breast tissue in BRCA1 mutation carriers.
Analysis of breast tissue samples using alternative methods of 
DNA damage assessment.
To explore the relationship between oestrogen metabolite 
concentration in serum and urine and DNA damage in breast 
tissue in BRCA1 mutation carriers.
Analysis of breast tissue, urine and blood samples for proxies 
of oestrogen levels and DNA damage.
To explore potential biomarkers of chemoprevention efficacy. Analysis of breast tissue, urine and blood samples for potential 
biomarkers of chemopreventive efficacy.
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design
A schematic overview of the trial is depicted in figure 1.
The crossover design allows comparison of outcomes 
from both treatments with the participant baseline; thus, 
each participant acts as their own control for both treat-
ment arms. Blinding or masking is not achievable given 
the nature of administration of goserelin (subcutaneous 
implant). Given that each participant will receive both 
treatments without blinding, randomisation was felt 
unnecessary, and alternate allocation of treatment groups 
in order of recruitment is adequate. The setting of the 
trial in tertiary care (family history breast clinics) reflects 
the main location for the ongoing care and management 
of this cohort.
selection of participants
Participants will be recruited from family history breast 
clinics within Northern Ireland as identified by clini-
cians and by posters and publicity regarding the trial 
presented and distributed at relevant public engagement 
events. The participant inclusion and exclusion criteria 
are outlined in table 2. The chief investigator (or appro-
priately trained delegate) will confirm eligibility against 
the inclusion/exclusion criteria.
description of interventions
Goserelin and anastrozole treatment
Participants will receive goserelin 3.6 mg by subcutaneous 
injection every 28 days for 12 weeks, simultaneously 
receiving oral anastrozole 1 mg per day for 12 weeks.
Tamoxifen treatment
Participants will receive oral tamoxifen 20 mg per day for 
12 weeks.
Washout period
On completion of the first treatment arm, participants will 
have a 4-week period of no treatment to allow washout of 
active substances, before commencing second treatment 
arm.
Figure 1 Chemoprevention in BRCA1 mutation carriers (CIBRAC) trial schema.
 o
n
 4 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023115 on 22 December 2018. Downloaded from 
5Campbell AM, et al. BMJ Open 2018;8:e023115. doi:10.1136/bmjopen-2018-023115
Open access
description of processes
Procedure for obtaining informed consent and trial arm 
allocation
Participants will receive an adequate explanation of the 
objectives, methods, potential risks and anticipated bene-
fits of the study. They will be given a current, ethically 
approved participant information sheet for their consid-
eration. Following this, informed consent will be obtained 
once women have had a minimum of 24 hours to consider 
trial entry and the opportunity to ask further questions. 
Following consent, participants will be provided with a 
copy of the signed consent form, with a copy filed in the 
patient notes, and the original retained in the site file, 
available for inspection if required.
No protocol-required assessments will be conducted 
until the consent form has been signed and dated by 
both the participant and the investigator. Participants will 
be provided the option to allow the use of blood samples, 
other body fluids and tissues obtained during testing, 
operative procedures, or other standard medical prac-
tices for further research purposes. Participants will be 
alternately allocated to treatment arms.
Replacement of participants
In the case of a participant request for withdrawal or 
failure to collect biological samples, the participant 
will be withdrawn from the study and a new participant 
enrolled into the treatment arm the original participant 
has been retracted from.
Percentage consenting to trial entry
Records will be kept of all the patient information sheets 
distributed to allow calculation of percentage of patients 
consenting to trial entry.
Compliance measurement
Participants will receive a medication diary card for each 
oral treatment at the same time the tablets (anastrozole 
for arm A and tamoxifen for arm B) are issued to track 
compliance.
Concomitant medication
Participants must be instructed not to take any medica-
tions (including herbal and over-the-counter remedies) 
during the study without prior consultation with the inves-
tigator. Any hormonal treatments (including all forms of 
hormonal contraception) are prohibited. Concomitant 
medications must be recorded in the patients’ notes at 
the time of initial consultation and any amendments 
documented at subsequent visits.
QOL assessment
Questionnaires will be completed on day 1 (baseline), 
day 84 (±3 days, following the end of the first arm) and 
day 196 (±3 days following the end of the second arm).
Two questionnaires will be used to assess health-related 
QOL:
1. European Organisation for Research and Treatment 
of Cancer Questionnaire to Quality of Life of Cancer 
patients, assessing QOL.
2. European Organisation for Research and Treatment 
of Cancer Questionnaire module to assess quality of 
life of patients with breast cancer, assessing treatment 
side effects and sexual dysfunction.
Recording of adverse events
An adverse event (AE) is any untoward medical occur-
rence (including deterioration of a pre-existing medical 
condition) in a subject administered an investigational 
medicinal product (IMP). The event does not necessarily 
have a causal relationship with treatment or usage. An 
adverse reaction (AR) is an AE that is suspected as having 
a causal relationship to the IMP. Each AE and its causality, 
severity and expectedness are assessed by the chief inves-
tigator (or nominated representative) and recorded in 
the patient notes. All IMPs in this study are licensed with 
well-defined safety profiles. As such, we will only record 
data relating to ARs in the case report form (CRF). If the 
event is classified as a serious adverse event (SAE), the 
reporting procedures as per Belfast Health and Social 
Care Trust (BHSCT) will also be followed. Follow-up will 
continue until all the necessary safety data for the event 
have been gathered and until the AR or SAE has resolved, 
returned to baseline or stabilised.
Pregnancy testing
Participants will be asked to provide a non-sterile urine 
sample (the initial stream) in a clean, non-sterile receiver. 
The sample will be used to perform a urinary human 
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age >18 years. BRCA1 mutation of uncertain 
significance.
Premenopausal. Personal history of breast or 
ovarian carcinoma.
Known pathogenic BRCA1 
mutation.
Previous risk-reducing breast 
or ovarian surgery.
Intact ovaries. Postmenopausal status.
No previous breast/ovarian 
carcinoma.
Concomitant use of alternative 
chemoprevention regimens.
No other previous 
malignancy.
Concomitant use of other 
hormonal agents less than 
1 month prior to enrolment.
No previous use of 
chemoprevention.
Contraindications to study drug 
therapies.
Willingness to use non-
hormonal contraception.
Contraindications to breast 
core biopsies.
Pregnancy or breast feeding.
Inability to give informed 
consent.
Having made a decision to 
proceed with risk-reducing 
surgery.
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chorionic gonadotropin (hCG) test in the clinic following 
the manufacturer’s standard operating procedure.
Pregnancy testing will be performed twice:
1. At the time of assessment of eligibility for the trial 
following consent, prior to the first arm treatment 
commencement.
2. On day 112±3 (week 16), prior to starting the second 
treatment arm.
Core biopsies
Biopsy samples will be collected as standard using a 14G 
core biopsy needle under ultrasound guidance in the 
Department of Radiology at Belfast City Hospital. Two 
core biopsies will be sharply dissected into at least four 
smaller samples (approximately 5 mm3 each) and placed 
in individual Eppendorf tubes, then snap-frozen with 
liquid nitrogen and stored for later use. Two core biopsies 
will be placed in individual formalin-containing sample 
pots, after which they will be formalin-fixed paraffin-em-
bedded (FFPE) as per standard operating procedures 
within the Belfast Trust.
Core biopsies will be taken on day 1 (baseline), day 84 
(±3 days following the end of the first arm) and day 196 
(±3 days following the end of the second arm).
Histopathological analysis
One FFPE sample will be assessed by a histopathologist to 
ensure adequate sampling of glandular tissue.
Comet assays
Two frozen biopsy specimens will be used to perform 
tissue-based comet assays to assess DNA damage.
Immunohistochemistry
One FFPE core biopsy sample will be sectioned and 
stained with antibodies against 53BP1 and phosphory-
lated histone A2 variant X (γH2AX) using conventional 
and fluorescent immunohistochemistry to assess DNA 
DSBs in these samples.
Additional sections will also be stained for RANK and 
RANKL as well as Ki67 using immunohistochemistry.
Mass spectrometry
Two frozen biopsy specimens will be used to examine 
concentrations of oestrogen metabolites 2-hydroxyestra-
diol (2-OHE2) and 4-hydroxyestradiol (4-OHE2), using 
ultra performance liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS).
Serum samples
Serum sampling will be performed on day 1 (baseline), 
day 84 (±3 days following the end of the first arm) and 
day 196 (± days following, end of the second arm). Partic-
ipants will undergo venepuncture with blood samples 
collected in two silica (clot activator) coated 10 mL blood 
sample tubes. After the minimum recommended clot-
ting time (60 min), blood samples will be centrifuged 
to allow separation of serum from blood cells, with the 
serum stored at −80°C in 1 mL aliquots in RNAse free 
tubes. Following sample accrual, samples will be thawed 
and serum 2-OHE2 and 4-OHE2 levels, and levels of depu-
rinating DNA adducts (common types of DNA damage 
caused by oestrogen metabolites) will be measured using 
UPLC-MS/MS.
Urine samples
Urine sampling will be performed on day 1 (baseline), day 
84 (±3 days following, end of the first arm) and day 196 
(±3 days following, end of the second arm). Mid-stream 
urine samples will be collected in sterile containers. 
Within 2 hours of collection samples will be centrifuged to 
separate debris from the urine and then stored at −80°C 
in 500 µL aliquots in RNAse free tubes. Following sample 
accrual. Samples will be thawed and urinary 2-OHE2 and 
4-OHE2 levels and levels of depurinating DNA adducts 
will be measured using UPLC-MS/MS.
Whole blood sampling
Each participant will provide one whole blood sample at 
one time point in the study. This will be performed at 
baseline (day 1), unless the patient is already enrolled 
and receiving treatment, in which case the whole blood 
sampling will be performed at the end of the treatment 
arm that they are currently receiving (day 84±3 days or 
day 196±3 days).
The whole blood samples will be collected at the same 
venepuncture session as serum sampling. Blood will be 
collected into one EDTA-coated tube and frozen/stored 
at −80°C in 1 mL aliquots. Samples will be retained for 
future use including DNA extraction.
The timeframe for interventions and assessments is 
summarised in table 3.
Comparisons
Each participant acts as her own control. The results from 
each individual’s set of samples (core biopsies, serum 
and urine) and questionnaires, taken at baseline, end of 
the first arm and end of the second arm will be compared. 
The results will not be compared between patients.
statistical analysis
This study is primarily aimed to determine acceptability 
and tolerability of the proposed chemopreventive treat-
ments. Therefore, no formal sample size calculation 
has been carried out, as the laboratory endpoints are all 
exploratory.
For these reasons, no formal statistical analysis is 
planned. Nonetheless, descriptive statistics will be used 
to summarise the principal and experimental findings of 
the study.
laboratory analysis
The proposed translational studies include performing 
comet assays on fresh-frozen breast core biopsies at 
baseline and after each treatment arm. The comet assay 
protocol has been optimised on breast cell cultures as 
well as fresh-frozen breast biopsy samples using neutral 
lysis techniques with automated scoring performed on a 
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high content screening system. FFPE breast core biopsy 
blocks are created at the same time points as fresh-frozen 
samples. Formation of γH2AX in response to DNA DSBs 
provides the basis for a sensitive immunohistochemical 
assay of DNA damage in human biopsies and has been 
optimised in FFPE breast samples with simultaneous 
staining for 53BP1, which localises to DNA strand breaks, 
with foci numbers proportional to DNA damage levels. 
Based on our hypothesis, the anticipated decrease in 
measurable DNA damage in response to oestrogen 
suppression would support the use of this strategy as a 
chemoprevention option in BRCA1 mutation carriers.
Further FFPE sections will be analysed for Ki67, RANK 
and RANKL expression to assess the effect of treatment 
on these markers of proliferation (Ki67) and proges-
terone signalling (RANK/RANKL). As the LHRHa used 
to suppress oestrogen will also result in progesterone 
suppression, it is expected that RANK and RANKL expres-
sion will also decrease. Given that inhibition of RANK 
has been shown to reduce breast cell proliferation in 
BRCA1 mutation carriers, it is possible that LHRHa treat-
ment might be an alternative way of downregulating this 
pathway and potentially decreasing the development of 
highly proliferative cells with grossly aberrant DNA repair 
observed in BRCA1 precancerous tissues with high levels 
of RANK/RANKL expression.15
Oestrogen metabolite levels in serum and urine will 
be measured using UPLC-MS/MS and have been opti-
mised on healthy volunteer samples with permission from 
Queen’s University Ethics Committee.
Patient and public involvement
BRCA1 and BRCA2 mutation carriers were involved 
throughout the design process via the Northern Ireland 
BRCA mutation carrier support group, BRCA Link NI. 
The study design was finalised with input from a BRCA 
patient advocate focus group, where the consensus was 
that inclusion of an active control treatment was more 
Table 3 Summary of assessments and interventions
Time point
<30 days 
prior to 
entry Week 1 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week 28
Week 
32 (end 
of trial)
Enrolment
Informed consent A+B
Baseline history A+B
  Eligibility screen and 
pregnancy test
A+B A+B
Treatment allocation A+B
Conmeds A+B A+B A A A+B A+B B B A+B A+B
Interventions
Start 
tamoxifen (12 weeks)
B A
Start anastrozole 
(12 weeks)
A B
Goserelin implant 
injection
A A A B B B
Assessments
Quality of life 
assessment
A+B A+B A+B
Core breast biopsies ×3 A+B A+B A+B
Blood samples 
for oestrogen and 
metabolite levels
A+B A+B A+B
Blood sample for whole 
blood
A+B A+B A+B
Urine samples for 
oestrogen and 
metabolite levels
A+B A+B A+B
Adverse event 
assessment
A+B A+B A+B A+B A+B A+B
A corresponds to treatment arm A of the study (goserelin and anastrozole followed by tamoxifen. B corresponds to treatment arm B, 
tamixofen followed by goserelin and anastrozole. 
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acceptable than placebo. Women within the group had 
experienced tamoxifen therapy as part of cancer treat-
ment and deemed potential side effects acceptable in the 
context of risk reduction. The BRCA mutation carrier 
cohort in Northern Ireland is overwhelmingly enthusi-
astic about chemoprevention clinical trials, resulting in 
a highly motivated patient group keen to contribute to 
future solutions to BRCA-related breast cancer risk. In 
keeping with this, the trial management group (TMG) 
for this study includes a BRCA1 mutation carrier.
dAtA CollECtIon And MAnAgEMEnt
The Investigator and study site staff will ensure that data 
collected on each subject are recorded on the CRF as 
accurately and completely as possible. Data management 
processes will be fully defined within the data manage-
ment plan for the study, held within the trial master file 
(TMF).
trIAl MAnAgEMEnt
trial Management group
The TMG will consist of an independent chair, the chief 
investigator, coinvestigators and clinical research nurse, 
as well as other relevant committee members, as defined 
within the TMG charter. The TMG will provide overall 
supervision of the trial on behalf of the trial funder and 
sponsors, and ensure that the trial is conducted according 
to Good Clinical Practice guidelines. The TMG will focus 
on progress of the trial, adherence to trial protocol and 
patient safety. The TMG will report to the BHSCT Clin-
ical Trial of an Investigational Medical Product  (CTIMP) 
Oversight Committee.
Frequency of meetings will be defined within the TMG 
charter but as a minimum will meet at least quarterly.
trial steering Committee
The BHSCT CTIMP Oversight Committee, which meets 
quarterly, acts as the Trial Steering Committee for chemo-
prevention in BRCA1 mutation carriers (CIBRAC).
Independent data monitoring committee
After review by the sponsor, it was not considered that an 
independent data monitoring committee was required 
for this trial due to its low-risk nature, in that the IMPs are 
not novel agents and are licensed agents with a well-de-
fined safety profile.
Monitoring
The sponsor has appointed the Clinical Research Moni-
toring Service within the Northern Ireland Clinical Trials 
Unit to undertake on site monitoring. An initial moni-
toring visit was carried out prior to the release of the 
final permissions letter by the sponsor. The first interim 
monitoring visit will take place within 6 months of the 
first patient being recruited. Further monitoring visits will 
take place approximately every 6 months from the date 
of the first visit. A close-out visit will occur once the last T
ab
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patient visit has been completed. A trial monitoring plan 
is available within the TMF.
The Standard Protocol Items: Recommendations for 
Interventional Trials checklist has been used in writing 
this report.26
EthICs And dIssEMInAtIon
Ethics
The Health and Social Care Research Ethics Committee 
B, as part of the Office for Research Ethics Committees 
Northern Ireland, awarded ethical approval for this study 
(REC Reference: 16/NI/0055, 21/4/16). A summary of 
amendments is given in table 4.
The IMPs used in this study are all licensed agents which 
are in common use in the treatment of breast cancer. 
They therefore have well-defined safety profiles available.
The women offered the opportunity to participate in 
this study are not patients with cancer, but rather are 
healthy premenopausal women who carry a pathogenic 
mutation in the BRCA1 gene. Although this is effectively 
a healthy volunteer study, it was felt it would not be appro-
priate to offer incentives for participation, although trav-
elling expenses are covered for trial hospital visits.
There was extensive patient and public involvement 
in the study design and development, to ensure that the 
proposed treatments and study procedures would be 
acceptable to patients.
trial registration
CIBRAC is registered as a clinical trial of an interven-
tional medicinal product on the European Clinical Trials 
Database, as EudraCT: 2016-001087-11. Trial registration 
data are provided in table 5.
dissemination
Academic dissemination of the study will be via publica-
tion in peer-reviewed journals in the relevant field (the 
International Committee of Medical Journal Editors 
criteria for authorship will be followed), and by presen-
tation at appropriate national and international meet-
ings. These may include meetings such as the biannual 
Symposium on Hereditary Breast and Ovarian Cancer 
in Montreal, Canada. A lay summary of the study results 
will be available, and all participants will be offered access 
to a copy of this. Furthermore, this will be shared with 
our partner Patient and Public Involvement (PPI) organ-
isation BRCA Link NI and disseminated through their 
website and social media channels. All mass spectrometry 
and sequencing data generated from this study and/or 
the future use of study samples will be deposited in appro-
priate publicly accessible repositories, with the associated 
anonymised metadata.
Author affiliations
1Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, 
UK
2Northern Ireland Cancer Trials Network, Belfast City Hospital, Belfast, UK
3BRCA Link NI, Ballynahinch, UK
Table 5 Trial registration data
Data category Information
Primary registry 
and trial registration 
number
EudraCT: 2016-001087-11
Date of registration in 
primary registry
9 March 2016
Sources of monetary 
or material support
Supported by a Cancer 
Research UK Clinical Research 
Training Fellowship
Sponsor Belfast Health and Social Care Trust
Contact for public 
queries
AMC (a.campbell@qub.ac.uk)
Contact for scientific 
queries
SAM  (s.mcintosh@qub.ac.uk), 
KIS (k.savage@qub.ac.uk)
Public title CIBRAC: chemoprevention in 
BRCA1 mutation carriers
Scientific title Chemoprevention in BRCA1 
mutation carriers (CIBRAC): an open 
allocation crossover trial assessing 
mechanisms of chemoprevention 
of goserelin and anastrozole versus 
tamoxifen
Countries of 
recruitment
UK (Northern Ireland)
Interventions Tamoxifen 20 mg daily 
(oral), goserelin 3.6 mg every 28 days 
(subcutaneously) plus anastrozole 
1 mg daily (oral)
Key inclusion criteria Ages eligible for study ≥18 years.
Sex eligible for study: female.
Known pathogenic germline BRCA1 
mutation.
Premenopausal.
No previous breast or ovarian risk-
reducing surgery.
Key exclusion criteria Personal history of breast or ovarian 
carcinoma.
Previous risk-reducing breast or 
ovarian surgery.
Postmenopausal status.
Study type Interventional.
Allocation: alternate treatment 
allocation, non-randomised, non-
blinded.
Primary purpose: prevention.
Phase II.
Date of first enrolment May 2017
Recruitment status Recruiting
Primary outcome Establish the acceptability of trial 
treatments as a chemopreventive 
strategy in BRCA1 mutation carriers, 
as measured by the number of 
patients entering the trial and 
compliance with treatment.
Key secondary 
outcomes
To establish tolerability of trial 
treatments and procedures.
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